

# Adrian Kee Keong

## TEO Ph.D.



 ateo@imcb.a-star.edu.sg

Dr. Teo is a principal investigator at the Institute of Molecular and Cell Biology (IMCB) and an assistant professor at Yong Loo Lin School of Medicine, National University of Singapore, using human pluripotent stem cells for disease modelling of diabetes, developing therapeutics and cell therapy. He is also a co-founder of BetaLife Pte Ltd focused on the use of stem cell therapy for diabetes patients.

### EDUCATION

He obtained B.Sc. (1st class honours) from the National University of Singapore. He completed his Ph.D. on stem cell biology with Ludovic Vallier at the University of Cambridge, under an A\*STAR Scholarship. He was also an Honorary Cambridge Commonwealth Trust Scholar. He trained with Rohit Kulkarni at Joslin Diabetes Center, Harvard Medical School, as a Juvenile Diabetes Research Foundation (JDRF) fellow, on pancreatic islet biology and diabetes.

### EXPERTISE

His research interests on pancreatic islet biology and diabetes.

### OTHERS

- A member of the Oxbridge Society of Singapore
- A member of the International Society for Stem Cell Research
- An EXCO member/Vice-Secretary of the Stem Cell Society Singapore

### ACADEMIC APPOINTMENTS

- Collaborated with Dr. Ray Dunn and Dr. Alan Colman at ES Cell International Pte. Ltd. on research involving human embryonic stem cells (hESCs)
- Joining the Institute of Medical Biology (IMB), Singapore, for an internship position as a Research Officer in the laboratory led by Dr. Ray Dunn
- Joining the laboratory of Ludovic Vallier, Ph.D. at the University of Cambridge to pursue his Ph.D.
- Post-doctoral fellow at IMB headed by Dr. Ray Dunn
- Post-doctoral fellow at the laboratory of Rohit Kulkarni, M.D. Ph.D. at Joslin Diabetes Center, Harvard Medical School
- Principal Investigator at the Institute of Molecular and Cell Biology (IMCB)
- Assistant Professor at the Department of Biochemistry and Department of Medicine, NUS Medicine, Singapore
- Assistant Professor at the School of Biological Sciences, Nanyang Technological University, Singapore
- Co-founder of BetaLife Pte Ltd focused on the use of stem cell therapy for diabetes patients

### SELECTED PUBLICATIONS

1. Tan, W.X., Sim, X.L., Khoo, C.M., Teo, K.K.A. 2023. Prioritization of type 2 diabetes associated genes for functional studies. *Nature Reviews Endocrinology*. 19: 477-486.
2. Lim, Y.X.L., Ding, S.L.S., Muthukumar, P., Teoh, S.H., Koh, Y.X., Teo, K.K.A. 2022. Tissue engineering of decellularized pancreas scaffolds for regenerative medicine in diabetes. *Acta Biomaterialia*. 157: 49-66.
3. Low, S.J.B., Lim, C.S., Tan, Y.S., Ding, S.L.S., Ng, H.J.N., Krishnan, V.G., Ang, S.F., Neo, W.Y.C., Verma, C.S., Hoon, S., Lim, S.C., Tai, E.S., Teo, K.K.A. 2021. Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC derived mutant  $\beta$  cells. *Nature Communications*. 12: 3133.
4. Loo, S.W.L., Vethe, H., Soetedjo, A.A.P., Paulo, J.A., Jasmen, J., Jackson, N., Bjorlykke, Y., Valdez, I.A., Vaudel, M., Barsnes, H., Gygi, S.P., Raeder, H., Teo, K.K.A., Kulkarni, R.N. 2019. Dynamic proteome profiling of human pluripotent stem cell-derived pancreatic progenitors. *Stem Cells*. 38: 542-555.